AAP
AVIR icon

Arax Advisory Partners’s Atea Pharmaceuticals AVIR Stock Holding History

Arax Advisory Partners’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6K Buy
+4,224
New +$21K ﹤0.01% 3971
2026
Q1 		– Sell
-8
Closed -$29 – 3819
2025
Q4 		$29 Sell
8
-191
-96% -$607 ﹤0.01% 3996
2025
Q3 		$577 Buy
+199
New +$680 ﹤0.01% 3352

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arax Advisory Partners's AVIR Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 4,224 shares worth $19.6K. The stake represents ﹤0.01% of the portfolio and ranks #3971 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in AVIR as recently as Q4 2025.

Arax Advisory Partners first reported a position in AVIR in Q3 2025 and has held it in 3 quarters since. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Arax Advisory Partners held 4,224 shares of Atea Pharmaceuticals worth $19.6K as of Q2 2026.
  • Atea Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3971 holding.
  • Arax Advisory Partners first reported a position in Atea Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.